🏍️ Eicher Motors – Q4 FY26 Results Summary
📊 Strong Financial Performance
-
💰 Revenue increased 24% to ₹23,408 crore
-
📈 Profit After Tax (PAT) grew 16.5% to ₹5,515 crore
-
⚡ EBITDA rose 22.8% to ₹5,785 crore
-
📊 EBITDA margin stayed strong at above 24%
🚀 Q4 FY26 Performance
-
Revenue grew 16%
-
EBITDA increased 20.4%
-
Net profit rose 11.6% year-on-year
🌍 Future Growth Investments
The company is investing in:
- ⚡ Electric Vehicles (EVs)
- 🌎 International expansion
- 🏭 Manufacturing capacity
- 💻 Technology initiatives
✅ All this is being done without major pressure on the balance sheet.
🎁 Dividend Announcement
-
💵 Final dividend declared: ₹82 per share
-
📈 Previous year dividend: ₹70 per share
🧠 Key Takeaway
Eicher Motors continues to grow strongly while maintaining healthy profits and margins.
This balance of growth, profitability, and disciplined spending is one of the main reasons investors value the company highly.
📢 Overall View: Positive & Strong Long-Term Growth Story 🚀
💊 Torrent Pharmaceuticals – Q4 FY26 Results Summary
📊 Revenue Performance-
💰 FY26 revenue grew 21.4% YoY
-
₹11,516 Cr → ₹13,980 Cr
-
🚀 Q4 FY26 revenue jumped 41.8% YoY
-
₹4,197 Cr in Q4
-
Growth was mainly supported by the consolidation of an acquired business.
💵 Profit Performance-
📈 FY26 net profit increased 11.9%
-
₹1,911 Cr → ₹2,138 Cr
-
⚠️ However, Q4 FY26 profit declined sharply:
-
₹364 Cr vs ₹498 Cr last year
-
🔻 Down 26.9% YoY
Main reasons for lower Q4 profit:-
Higher finance costs
-
Increased depreciation & amortisation (D&A)
-
Exceptional charges
-
Forex and hedging losses
📉 Margin Performance-
EBITDA margin slightly reduced:
-
32.3% → 31.3%
-
Net profit margin also declined:
-
Due to higher borrowing and acquisition-related expenses
✅ Core business operations remain stable as Q4 EBITDA margin stayed near 32%.
📈 EPS & Shareholder Impact-
EPS grew 13.2%
-
₹56.47 → ₹63.92
-
✅ No equity dilution
-
Growth came from actual earnings improvement.
⚠️ Key Concern-
The company now carries very high intangible assets from acquisitions.
-
📌 Amortisation expenses are expected to remain high for several years.
-
This may continue to pressure reported profits.
🧠 Overall Takeaway
✅ Strong revenue growth
✅ Acquisition boosting scale rapidly
✅ Core operations stable
⚠️ Profit margins under pressure
⚠️ Higher finance and amortisation costs impacting earnings
📢 Overall View: Growth remains strong, but short-term profitability is facing pressure due to acquisition-related costs.
🏢 Prestige Estates Projects – Q4 & FY26 Results Summary
📊 Revenue Performance-
🚀 FY26 revenue surged 72.6% YoY
-
₹7,349 Cr → ₹12,685 Cr
-
🔥 Q4 FY26 revenue jumped 166.5% YoY
-
₹1,528 Cr → ₹4,074 Cr
-
This was the company’s strongest quarter ever.
✅ Growth was driven by:-
Faster project completions
-
Higher property handovers
-
Strong execution momentum
💵 Profit Performance-
📈 FY26 PAT more than doubled
-
₹617 Cr → ₹1,305 Cr
-
🔥 Growth: +111.6%
-
🚀 Q4 FY26 PAT surged sharply
-
₹292 Cr vs ₹43 Cr last year
-
🔥 Up 577% YoY
Key support factors:-
Strong operating leverage
-
Deferred tax benefits
-
Higher revenue scale
📉 Margin Performance-
EBITDA margin declined:
-
39.5% → 33.1%
-
Q4 EBITDA margin fell further to 26.5%
⚠️ Main reasons:-
Higher land costs
-
Increased contractor expenses
-
More lower-margin projects completed
✅ However, net profit margin improved slightly due to tax benefits and better finance cost absorption.
📈 Growth & Balance Sheet-
🏗 Inventory increased 26.3%
-
₹31,883 Cr → ₹40,252 Cr
-
💰 Customer advances rose 31.3%
-
₹25,073 Cr → ₹32,944 Cr
-
📉 Finance costs grew slower than revenue
-
Positive sign for future profitability
🧠 Overall Takeaway
✅ Massive revenue growth
✅ Record quarterly performance
✅ Strong project execution and demand
✅ Robust future pipeline
⚠️ Operating margins under pressure from rising costs
📢 Overall View: Strong growth momentum with healthy demand, though profitability margins are slightly moderating due to higher execution costs.
💊 Sun Pharmaceutical Ind – Q4 FY26 Results Summary
📊 Revenue Performance-
📈 FY26 revenue increased 11.2% YoY
-
₹52,578 Cr → ₹58,462 Cr
-
🚀 Q4 FY26 revenue grew 12.8% YoY
-
₹12,959 Cr → ₹14,612 Cr
-
⚠️ Q4 revenue declined slightly compared to Q3 due to seasonal softness.
✅ Growth drivers:-
Strong domestic formulations business
-
Expansion in specialty medicines
-
Global generic business growth
💵 Profit Performance-
📈 FY26 PAT increased 5% YoY
-
₹10,929 Cr → ₹11,479 Cr
-
💹 EPS improved slightly
-
₹45.6 → ₹47.8
⚠️ Profit growth was lower than revenue growth mainly because of:-
Higher tax expenses
-
Exceptional items during FY26
📉 Margin Performance-
✅ EBITDA margin remained stable at around 31.5%
-
⚠️ Net profit margin reduced:
-
20.8% → 19.6%
-
Higher effective tax rate
-
Increased employee and operating costs
🔬 Investment & Expansion-
🧪 R&D spending increased to ₹3,474 Cr
-
The company continues investing heavily in:
-
Specialty drugs
-
Product pipeline
-
Global expansion
✅ Importantly, these investments were made without hurting EBITDA margins.
⚠️ Areas to Monitor-
👨💼 Employee costs rose 14.5%
-
📦 Other expenses increased 13.3%
-
Operating leverage benefits are yet to fully reflect in profits.
🧠 Overall Takeaway
✅ Strong and stable revenue growth
✅ Healthy global and specialty business momentum
✅ EBITDA margins remained strong
✅ Continued investment in future growth areas
⚠️ PAT growth impacted by higher taxes and operating costs
📢 Overall View: A financially strong pharma company with stable margins, strong global growth, and continued long-term investment in specialty business expansion.
Disclaimer:
Content shared through our blogs are for information and education purposes only and should not be treated as investment or trading advice. Please do your own analysis or take independent professional financial advice before making any investments based on your own personal circumstances. Investment in securities are subject to market risks, please carry out your due diligence before investing. And last but not the least, past performance is not indicative of future returns.
Open demat account with India's No-1 broker ZERODHA....
